EUVIMEDEUVIMED entdecken
Crossref

1385-P: Real-World Reduction in Albuminuria with Finerenone in Patients with Diabetic Chronic Kidney Disease

DAKSHATA A. PADHYE, SONALI PATANGE

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1385-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von DAKSHATA A. PADHYE und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Albuminuria is a validated surrogate of cardiorenal risk in diabetic CKD. Finerenone reduced albuminuria in FIDELIO-DKD and FIGARO-DKD, but real-world data remain limited.

Methods

This retrospective analysis included 83 patients with diabetic CKD treated with finerenone. Mean age was 63 years (95% CI: 61-65) and mean diabetes duration was 17 years (95% CI: 15-19). Urinary albumin-to-creatinine ratio (UACR) was assessed at baseline and follow-up, at and categorized as normal (<30 mg/g), microalbuminuria (30-300 mg/g), or macroalbuminuria (>300 mg/g). A ≥30% reduction in UACR was predefined as a clinically meaningful response. GraphPad 10.6.1 was used for statistical analysis Results: Mean UACR decreased significantly from 274.6 mg/g to 144.8 mg/g, with absolute reduction of 129.9 mg/g and a mean relative reduction of 44.6% (p = 0.0033; Cohen’s d = 0.46). Median UACR declined from 154.2 to 55.2 mg/g, with consistent reductions across interquartile ranges, indicating a broad distributional shift. Overall, 38 patients (45.8%) improved their albuminuria category, 44 (53.0%) remained stable, and one patient worsened. A ≥30% reduction in UACR was achieved in approximately 78% of patients. Concomitant SGLT2 inhibitor use was associated with numerically greater UACR reductions. Glycemic control remained stable, with no significant change in HbA1c (8.52% to 8.17%; p = 0.1185)

Conclusion

In patients with T2DM and CKD, finerenone led to clinically meaningful reduction in albuminuria, with high responder rates and minimal progression. Patients receiving concomitant SGLT2 inhibitors with finerenone demonstrated numerically greater reductions in UACR compared with those not on SGLT2 inhibitors. The magnitude and pattern of UACR reduction are directionally consistent with FIDELIO-DKD and FIGARO-DKD trials, supporting the real-world translational relevance of finerenone-mediated renal risk modification independent of glycemic effects. Disclosure D.A. Padhye: None. S. Patange: None.

Zitieren

APA

PADHYE, D. A., & PATANGE, S. (2026). 1385-P: Real-World Reduction in Albuminuria with Finerenone in Patients with Diabetic Chronic Kidney Disease. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1385-p

Vancouver

PADHYE DA, PATANGE S. 1385-P: Real-World Reduction in Albuminuria with Finerenone in Patients with Diabetic Chronic Kidney Disease. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1385-p

BibTeX
@article{PADHYE2026,
  author = {PADHYE, DAKSHATA A. and PATANGE, SONALI},
  title = {1385-P: Real-World Reduction in Albuminuria with Finerenone in Patients with Diabetic Chronic Kidney Disease},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1385-p}
}
Kostenlos starten →